Fuzapladib sodium – management of acute pancreatitis beyond supportive care
Nov 07, 2024
Bronx Clinical Theater
GI
This presentation will give a short overview of the management of pancreatitis as it relates to symptomatic and supportive care. However, the session will heavily focus on fuzapladib sodium, which has received conditional approval by the FDA as Panoquel-CA1. All data available for fuzapladib sodium will be discussed. Limitations of use will also be discussed.
- Comprehensive summary of symptomatic and supportive care for dogs with acute pancreatitis
- Mechanism of action of fuzapladib sodium
- Clinical experience with fuzapladib sodium
- Limitations of use of fuzapladib sodium
Sponsored by:
